AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7696061 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 40
Study 2715372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of cefotetan (1 g)
Number of subjects: 12
Study 2715372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of cefotetan (1 g)
Number of subjects: 12
Study 318916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous loading course of 5-fluorouracil
Number of subjects: 462
Study 318916 — intervention group
Group type: COMPARATOR
Intervention: Weekly intravenous schedule of 5-fluorouracil
Number of subjects: 462
Study 318916 — intervention group
Group type: COMPARATOR
Intervention: Nontoxic schedule of 5-fluorouracil
Number of subjects: 462
Study 318916 — intervention group
Group type: COMPARATOR
Intervention: Oral schedule of 5-fluorouracil
Number of subjects: 462
Study 30431171 — intervention group
Group type: COMPARATOR
Intervention: Fractional CO2 laser alone
Number of subjects: 30
Study 30431171 — intervention group
Group type: COMPARATOR
Intervention: Fractional CO2 laser combined with topical TXA
Number of subjects: 30
Study 30431171 — intervention group
Group type: COMPARATOR
Intervention: Fractional CO2 laser combined with intradermal TXA
Number of subjects: 30
Study 24804687 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients
Number of subjects: 80
Study 24804687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 25892016 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine treatment with 1.25 mg intravitreal bevacizumab every 12 weeks after loading doses
Number of subjects: 331
Study 25892016 — intervention group
Group type: COMPARATOR
Intervention: As-needed treatment with 1.25 mg intravitreal bevacizumab every 12 weeks after loading doses
Number of subjects: 331
Study 24098469 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (4 x 5 g/d for 5 days followed by 5 g/d)
Number of subjects: 56
Study 24098469 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose at the same dosage)
Number of subjects: 56
Study 24098469 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation associated with strength training
Number of subjects: 56
Study 24098469 — intervention group
Group type: COMPARATOR
Intervention: Placebo associated with strength training
Number of subjects: 56
Study 24098469 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 56
Study 24098469 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 56
Study 22016254 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEEs; 0.625 mg/day)
Number of subjects: 2
Study 22016254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 20034232 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC, 1.8 g/day, 3 days)
Number of subjects: 55
Study 20034232 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid (ALA, 1.2 g/day, 3 days)
Number of subjects: 55
Study 20034232 — intervention group
Group type: EXPERIMENTAL
Intervention: taurine (TAU, 3 g/day, 3 days)
Number of subjects: 55
Study 20034232 — intervention group
Group type: COMPARATOR
Intervention: control group (CON)
Number of subjects: 55
Study 16955723 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative magnesium supplementation
Number of subjects: 40
Study 16955723 — intervention group
Group type: COMPARATOR
Intervention: No preoperative magnesium supplementation (Control)
Number of subjects: 40
Study 15628231 — intervention group
Group type: EXPERIMENTAL
Intervention: Movalis
Number of subjects: 30
Study 11754136 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (n = 6)
Number of subjects: 15
Study 11754136 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 15
Study 9358198 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem administered by injection over 2 minutes
Number of subjects: 9
Study 9358198 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem administered by injection over 3 minutes
Number of subjects: 9
Study 9358198 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem administered by injection over 5 minutes
Number of subjects: 9
Study 8205299 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 6 mg
Number of subjects: 10
Study 8205299 — intervention group
Group type: COMPARATOR
Intervention: Spirapril 6 mg with isradipine 5 mg
Number of subjects: 10
Study 3074458 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 25
Study 3074458 — intervention group
Group type: EXPERIMENTAL
Intervention: Ispaghula and Calcium
Number of subjects: 25
Study 30871048 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Formula (EF) supplemented with AA and DHA
Number of subjects: 176
Study 30871048 — intervention group
Group type: COMPARATOR
Intervention: Standard Formula (SF)
Number of subjects: 176
Study 30871048 — intervention group
Group type: COMPARATOR
Intervention: Breastfed infants (BF)
Number of subjects: 176
Study 28002359 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY‐TT coadministered with routine childhood vaccines
Number of subjects: 2095
Study 28002359 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY‐TT
Number of subjects: 2095
Study 28002359 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY‐TT coadministered with childhood vaccines
Number of subjects: 2095
Study 25815491 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular inhalation of salmeterol/fluticasone propionate (SM/FP)
Number of subjects: 112
Study 25815491 — intervention group
Group type: COMPARATOR
Intervention: Intermittent inhalation of salmeterol/fluticasone propionate (SM/FP)
Number of subjects: 112
Study 25815491 — intervention group
Group type: COMPARATOR
Intervention: Comparison of standard group vs intermittent group
Number of subjects: 112
Study 25815491 — intervention group
Group type: COMPARATOR
Intervention: Growth velocity and BMI
Number of subjects: 112
Study 23490288 — intervention group
Group type: EXPERIMENTAL
Intervention: LOS + HCTZ (losartan 50 mg/d + hydrochlorothiazide 12.5 mg/d)
Number of subjects: 112
Study 23490288 — intervention group
Group type: COMPARATOR
Intervention: LOS + CCB (losartan 50 mg/d + amlodipine 5 mg/d)
Number of subjects: 112
Study 23490288 — intervention group
Group type: EXPERIMENTAL
Intervention: LOS + HCTZ
Number of subjects: 112
Study 23490288 — intervention group
Group type: COMPARATOR
Intervention: LOS + CCB
Number of subjects: 112
Study 21763252 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased chest compression fraction (CCF); median CCF 71%; median compression rate 110/min
Number of subjects: 2103
Study 21763252 — intervention group
Group type: COMPARATOR
Intervention: CCF category 0-40% (reference group)
Number of subjects: 2103
Study 21763252 — intervention group
Group type: EXPERIMENTAL
Intervention: CCF category 41-60%
Number of subjects: 2103
Study 21763252 — intervention group
Group type: EXPERIMENTAL
Intervention: CCF category 61-80%
Number of subjects: 2103
Study 17698328 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (max. 1.8 mg/kg/d)
Number of subjects: 1326
Study 15998535 — intervention group
Group type: EXPERIMENTAL
Intervention: Human saliva (HS)
Number of subjects: 70
Study 15998535 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucin-based artificial saliva (MC)
Number of subjects: 70
Study 15998535 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose-containing saliva (CM)
Number of subjects: 70
Study 15998535 — intervention group
Group type: EXPERIMENTAL
Intervention: Deionized water (DW)
Number of subjects: 70
Study 15998535 — intervention group
Group type: COMPARATOR
Intervention: No lubrication (UN)
Number of subjects: 70
Study 15309547 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg) and alpha-tocopherol (1,200 IU) daily for 37 days
Number of subjects: 12
Study 15309547 — intervention group
Group type: COMPARATOR
Intervention: Glucose placebo
Number of subjects: 12
Study 15309547 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and alpha-tocopherol
Number of subjects: 12
Study 15309547 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study 11145854 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha therapy
Number of subjects: 44
Study 11145854 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma therapy
Number of subjects: 44
Study 11145854 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin therapy
Number of subjects: 44
Study 11145854 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 44
Study 9302748 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent live attenuated influenza A vaccine (10^6 TCID50)
Number of subjects: 1126
Study 9302748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1126
Study 8161479 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril calcium (7.5-30 mg twice a day)
Number of subjects: 1500
Study 8161479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 3532654 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (T10‐S5) with intermittent 0.5% bupivacaine during the first 24 postoperative hours
Number of subjects: 14
Study 3532654 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 14
Study 3532654 — intervention group
Group type: COMPARATOR
Intervention: Comparison between epidural and general anesthesia groups
Number of subjects: 14
Study 29991140 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality games with dynamic arm support for 20 weeks
Number of subjects: 16
Study 29991140 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study 27071830 — intervention group
Group type: EXPERIMENTAL
Intervention: Multielectrode pulmonary vein isolation (MEA)
Number of subjects: 120
Study 27071830 — intervention group
Group type: COMPARATOR
Intervention: Standard focal irrigated radiofrequency ablation (STA)
Number of subjects: 120
Study 24798484 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 408
Study 22135712 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor control exercises
Number of subjects: 172
Study 22135712 — intervention group
Group type: COMPARATOR
Intervention: Graded activity
Number of subjects: 172
Study 20565257 — intervention group
Group type: EXPERIMENTAL
Intervention: Casp8p41 content in memory CD4 T cells
Number of subjects: 0
Study 20565257 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in Casp8p41 content
Number of subjects: 0
Study 20565257 — intervention group
Group type: EXPERIMENTAL
Intervention: Casp8p41 change
Number of subjects: 0
Study 17673104 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternatives to the randomized controlled trial (RCT)
Number of subjects: 0
Study 17673104 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic and economic evaluation of whole-population interventions
Number of subjects: 0
Study 16124844 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid HIV test
Number of subjects: 103
Study 16124844 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV test
Number of subjects: 103
Study 11754709 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (n = 222)
Number of subjects: 620
Study 11754709 — intervention group
Group type: COMPARATOR
Intervention: Needle-insertion control (n = 203)
Number of subjects: 620
Study 11754709 — intervention group
Group type: COMPARATOR
Intervention: Relaxation control (n = 195)
Number of subjects: 620
Study 11754709 — intervention group
Group type: COMPARATOR
Intervention: All conditions (including counseling)
Number of subjects: 620
Study 10960435 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (endoscopic variceal ligation, nadolol, and sucralfate)
Number of subjects: 122
Study 10960435 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal ligation only
Number of subjects: 122
Study 8822220 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with hyperoxic gas mixtures at fixed frequency and tidal volume (twice resting ventilation)
Number of subjects: 16
Study 8822220 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with hypoxic gas mixture
Number of subjects: 16
Study 8822220 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing with hyperoxic gas mixture
Number of subjects: 16
Study 1444724 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 250 mg
Number of subjects: 36
Study 1444724 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 500 mg
Number of subjects: 36
Study 1444724 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (both doses)
Number of subjects: 36
Study 1444724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 3936167 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate (GSTM)
Number of subjects: 77
Study 3936167 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine (PEN)
Number of subjects: 77
Study 30806453 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred care approach with educational interventions and continuous supervision
Number of subjects: 1153
Study 30806453 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1153
Study 30806453 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred care approach
Number of subjects: 1153
Study 29514721 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 17
Study 29514721 — intervention group
Group type: COMPARATOR
Intervention: Regular coffee with sugar
Number of subjects: 17
Study 29514721 — intervention group
Group type: COMPARATOR
Intervention: Regular coffee
Number of subjects: 17
Study 29514721 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 17
Study 27114197 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil on-demand (PRN)
Number of subjects: 4354
Study 27114197 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil once-daily (OAD)
Number of subjects: 4354
Study 27114197 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil 10 mg (low dose) PRN
Number of subjects: 4354
Study 27114197 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil 20 mg (high dose) PRN
Number of subjects: 4354
Study 27114197 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil 2.5 mg (low dose) OAD
Number of subjects: 4354
Study 27114197 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil 5 mg (high dose) OAD
Number of subjects: 4354
Study 27114197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4354
Study 24888915 — intervention group
Group type: EXPERIMENTAL
Intervention: PAMG-1 test
Number of subjects: 120
Study 24888915 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP-1 test
Number of subjects: 120
Study 24888915 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazine test
Number of subjects: 120
Study 24888915 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PAMG-1 and Nitrazine test
Number of subjects: 120
Study 24888915 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PAMG-1 and IGFBP-1 test
Number of subjects: 120
Study 22569995 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (500 mg aspirin and 300 mg clopidogrel before intervention, followed by 100 mg aspirin and 75 mg clopidogrel daily for 6 months)
Number of subjects: 80
Study 22569995 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (500 mg aspirin before intervention, followed by placebo instead of clopidogrel)
Number of subjects: 80
Study 22569995 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 80
Study 22569995 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 80
Study 20974577 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone (150 mg IM biweekly)
Number of subjects: 104
Study 20974577 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (250 mg IM biweekly)
Number of subjects: 104
Study 20974577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 18579642 — intervention group
Group type: EXPERIMENTAL
Intervention: High-K diet (either a high fruit/vegetable diet or the DASH diet) for 8 weeks
Number of subjects: 413
Study 18579642 — intervention group
Group type: COMPARATOR
Intervention: Low-K control diet for 8 weeks
Number of subjects: 413
Study 18579642 — intervention group
Group type: COMPARATOR
Intervention: Low-K control diet for 3 weeks prior to random assignment
Number of subjects: 413
Study 15808404 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT2 fast acetylator genotype
Number of subjects: 54220
Study 12744952 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntactic gender decision task (GEN)
Number of subjects: 0
Study 12744952 — intervention group
Group type: EXPERIMENTAL
Intervention: Word category decision task (WC)
Number of subjects: 0
Study 12744952 — intervention group
Group type: COMPARATOR
Intervention: Physical baseline task (BASE)
Number of subjects: 0
Study 10511370 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm cell sorting with flow cytometry
Number of subjects: 0
Study 10511370 — intervention group
Group type: COMPARATOR
Intervention: Preferential lysis method
Number of subjects: 0
Study 8758241 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen (PSA) testing
Number of subjects: 2054
Study 8758241 — intervention group
Group type: COMPARATOR
Intervention: Digital rectal examination (DRE)
Number of subjects: 2054
Study 8758241 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PSA (> 10 micrograms/l) and DRE
Number of subjects: 2054
Study 31287147 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency intermittent theta burst stimulation (iTBS) over contralateral motor cortex of the most affected leg, once a day for two weeks; 10 bursts containing three pulses at 50 Hz repeated at 200 ms intervals (5 Hz) every 10 s for a total of 600 stimuli
Number of subjects: 17
Study 31287147 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control group)
Number of subjects: 17
Study 28428728 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-Face (F2F) exercise intervention
Number of subjects: 65
Study 28428728 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise intervention
Number of subjects: 65
Study 28428728 — intervention group
Group type: COMPARATOR
Intervention: Control (standard prenatal care/GDM dietary counseling)
Number of subjects: 65
Study 25669986 — intervention group
Group type: EXPERIMENTAL
Intervention: Naptumomab estafenatox (Nap) plus IFN-α
Number of subjects: 0
Study 25669986 — intervention group
Group type: COMPARATOR
Intervention: IFN-α
Number of subjects: 0
Study 24468257 — intervention group
Group type: EXPERIMENTAL
Intervention: rhC1INH (50 IU/kg to maximum 4,200 IU/treatment)
Number of subjects: 75
Study 24468257 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 75
Study 22834291 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion therapy with remaxol (800 ml/day)
Number of subjects: 139
Study 22834291 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion therapy with sterofundine-G-5
Number of subjects: 139
Study 22834291 — intervention group
Group type: COMPARATOR
Intervention: Infusion therapy with ringer's lactate and 10% glucose solution (1:1)
Number of subjects: 139
Study 22834291 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion therapy with remaxol
Number of subjects: 139
Study 18510696 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT)
Number of subjects: 42
Study 18510696 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 42
Study 15816817 — intervention group
Group type: EXPERIMENTAL
Intervention: In-service telephone recruitment
Number of subjects: 0
Study 15816817 — intervention group
Group type: EXPERIMENTAL
Intervention: Meetings with prospective participants
Number of subjects: 0
Study 15816817 — intervention group
Group type: COMPARATOR
Intervention: Initial recruitment strategies
Number of subjects: 0
Study 12628619 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for nicotine dependence
Number of subjects: 224
Study 14727847 — intervention group
Group type: EXPERIMENTAL
Intervention: Small batch of propranolol (6 kg)
Number of subjects: 28
Study 14727847 — intervention group
Group type: EXPERIMENTAL
Intervention: Large batch of propranolol (60 kg)
Number of subjects: 28
Study 14727847 — intervention group
Group type: EXPERIMENTAL
Intervention: Small batch of metoprolol (14 kg)
Number of subjects: 28
Study 14727847 — intervention group
Group type: EXPERIMENTAL
Intervention: Large batch of metoprolol (66 kg)
Number of subjects: 28
Study 8788259 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral catheter tip location
Number of subjects: 39
Study 8788259 — intervention group
Group type: COMPARATOR
Intervention: Central catheter tip location in the superior vena cava
Number of subjects: 39
Study 8788259 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheters associated with thrombosis
Number of subjects: 39
Study 1378382 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1 mg/kg
Number of subjects: 38
Study 1378382 — intervention group
Group type: COMPARATOR
Intervention: Methohexital 0.7 mg/kg
Number of subjects: 38
Study 1378382 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg
Number of subjects: 38
Study 1378382 — intervention group
Group type: COMPARATOR
Intervention: Methohexital 1.5 mg/kg
Number of subjects: 38
Study 6543314 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 80 mg single dose
Number of subjects: 12
Study 6543314 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide 5‐mononitrate (IS‐5‐MN) 80 mg single dose
Number of subjects: 12
Study 31195354 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with cetuximab (anti-EGFR-directed monoclonal antibody) in combination with capecitabine and cisplatin
Number of subjects: 630
Study 31195354 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with capecitabine and cisplatin
Number of subjects: 630
Study 29370022 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebound self-tonometry
Number of subjects: 40
Study 29370022 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% ophthalmic solution
Number of subjects: 40
Study 26867970 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid for RAVES RCT
Number of subjects: 127